Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CM-AT Open Label Extension in Children With Autism
NCT00912691Phase 3Completed
- Sponsor
- Curemark
- Start
- Jan 2010
- Primary completion
- Feb 2016
- Modality
- Therapeutic Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of CM-AT in Autism Spectrum Disorder (ASD), sponsored by Curemark. Started Jan 2010; status: completed.
02
Drugs
CM-AT
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on NCT00912691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00912691.